{"entity":{"id":"nct07567846","kind":"trial","name":"A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer","aka":[],"tldr":"A phase 1/2 trial of GDC-1261 in prostate cancer, run by Genentech, Inc., now recruiting.","summary":"A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer is a phase 1/2 interventional study registered as NCT07567846 by Genentech, Inc., with 260 participants planned, started 2026-04-29 and due to reach its primary completion in 2027-11-30. Interventions recorded: GDC-1261.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07567846","url":"https://clinicaltrials.gov/study/NCT07567846"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["flatiron-health"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07567846","phase":"1/2","setting":"A Phase I/II Dose-escalation and Expansion Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Patients With Advanced or Metastatic Prostate Cancer","sponsor":"Genentech, Inc.","enrolled":260,"outcomes":[]},"route":"/trials/nct07567846/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"company":[{"id":"flatiron-health","kind":"company","name":"Flatiron Health (Roche)","route":"/companies/flatiron-health/"}]}}